The Motley Fool Discussion Boards

Previous Page

Social Clubs / Last RoundUp


Subject:  Re: My 2018 review Date:  1/4/2019  12:19 PM
Author:  NajdorfSicilian Number:  3451 of 3782

Down 0.64% officially [Yay? :( ]. 2019 looking better so far.

Eyeballing ALNY and SRPT in the midcap biotech space. Not for the faint of heart. Definitely for long-term investors and those interested in gene therapies, RNA treatments.
Copyright 1996-2021 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us